Drug Trial Radar · NCT04825730
Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy
Last checked: Nov 19, 2026Latest source record: Sep 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
14
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
Dec 1, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- R-BioIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is conducted to assess the long-term safety of "jointstem" in patients with degenerative knee arthritis who participated in the previous BS-JS-IIT1 investigator initiated trial.
Conditions
- Degenerative Arthritis
- Knee Arthritis
Interventions
JOINTSTEMDrug
JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 60 Month
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.